This is a working overview of lyophilized powder, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-06-06. Anything still debated is marked as such rather than presented as settled.
Body composition is assessed with dual-energy X-ray absorptiometry or comparable methods, which separate fat mass from lean mass. Reported losses include both compartments, and the ratio between them is a subject of ongoing analysis rather than a settled result. Waist circumference, blood pressure, and lipid panels are collected as supporting measures. Resting energy expenditure and substrate oxidation are measured in smaller mechanistic studies, where glucagon receptor activity is expected to matter. These substudies are typically short and small, so their findings carry wide uncertainty.
Interpretation depends on study phase and duration. Phase 2 programs are powered for weight and safety signals, not for cardiovascular or renal outcomes, which require event-driven designs. Gastrointestinal events such as nausea, diarrhea, vomiting, and constipation are the most frequently reported adverse effects and tend to cluster around dose escalation. Small increases in heart rate have been described. Because follow-up after treatment discontinuation is limited, questions about weight regain and durability are open rather than answered.
The three-receptor design places retatrutide in a distinct category relative to older incretin-based therapies. Single agonists target one receptor, and dual agonists target two. Adding a third target broadens the pharmacological footprint and introduces new trade-offs among efficacy, tolerability, and glucose control. How these trade-offs resolve in large trials is a central focus of current research.
Retatrutide is an investigational peptide studied for obesity and type 2 diabetes. It is a single synthetic molecule designed to activate three metabolic receptors simultaneously. The compound belongs to the incretin mimetic family, a group of peptides that imitate gut hormones involved in appetite and glucose control. Its research code is LY3437943, and it remains under clinical study rather than cleared for routine medical use.
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
| Property | Value | Notes |
|---|---|---|
| Trial design | Randomized, double-blind, placebo-controlled | Frequently includes dose-escalation arms |
| Weight endpoint | Percent change from baseline | Reported at a prespecified week |
| Liver fat endpoint | MRI proton density fat fraction | Non-invasive imaging measure |
| Body composition method | Dual-energy X-ray absorptiometry | Separates fat mass from lean mass |
| Common adverse events | Nausea, diarrhea, vomiting | Reported most often during dose escalation |
Dissolution behavior depends on the amino acid sequence, the counterion content, and the buffer chosen. Many peptides disperse readily in water or mild aqueous buffers, while others require a small amount of organic co-solvent or a change in pH. Adsorption to plastic and glass surfaces can reduce the concentration of a solution over time, particularly at low concentrations. Filtration before analysis removes particulates, and aliquoting limits repeated freeze-thaw cycles that stress the material.
Research-grade peptide material is commonly supplied as a lyophilized powder, a form that limits degradation during transport and storage. Standard practice keeps such material cold and protected from light and moisture, with tighter conditions used for long-term archives. Once dissolved, solutions are generally considered less stable than the dry powder and are handled on shorter timescales. These established conventions derive largely from general peptide chemistry rather than from compound-specific evidence alone.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
In chromatography, endcapping refers to the replacement of accessible silanol groups in a bonded stationary phase by trimethylsilyl groups. End-capped columns have much lower residual silanol group activity compared to non-endcapped columns. Endcapped columns show decreased retention for hydrogen bond acceptors, such as ionized bases, and increased retention for protonated bases.
However, this method is not truly analogous to protein structural alignment techniques because it computationally predicts the structures of the RNA input sequences rather than requiring experimentally determined structures as input. Although computational prediction of the protein folding process has not been particularly successful to date, RNA structures without pseudoknots can often be sensibly predicted using free energy-based scoring methods that account for base pairing and stacking.
=== Law enforcement === GC–MS is increasingly used for detection of illegal narcotics, and may eventually supplant drug-sniffing dogs.[1] A simple and selective GC–MS method for detecting marijuana usage was recently developed by the Robert Koch Institute in Germany. It involves identifying an acid metabolite of tetrahydrocannabinol (THC), the active ingredient in marijuana, in urine samples by employing derivatization in the sample preparation. GC–MS is also commonly used in forensic toxicology to find drugs and/or poisons in biological specimens of suspects, victims, or the deceased. In drug screening, GC–MS methods frequently utilize liquid-liquid extraction as a part of sample preparation, in which target compounds are extracted from blood plasma.
MyCoPortal, described by Miller and Bates as a portal providing access to digitized specimen data from participating fungaria, forms part of a broader effort to make fungal specimen information discoverable online. By 2021, the portal was reported to contain 7,394,281 occurrence records from collections spanning universities, botanic gardens, museums, and government agencies. Linked specimen metadata and sequence data can be aggregated through biodiversity portals such as GBIF, BISON, iDigBio, and MyCoPortal to support mapping, biodiversity research, and the tracking of disease records over time. The Macrofungi Collection Consortium, a National Science Foundation-funded digitization project, resulted in the digitization of approximately 1.25 million United States macrofungal specimens between 2012 and 2017. The AMUNATCOLL project digitized the Szulczewski fungarium and other natural history collections at Adam Mickiewicz University, providing open access to high-quality scans and metadata. Digitization can be extended by linking specimen records to derivative data such as gene sequences and images, keeping disparate evidence connected to a specimen record over time. Specialized collection portals can also integrate specimen records, images, georeferences, checklists, and synonymy management; for example, the Consortium of Lichen Herbaria reported more than 3.5 million occurrence records from 181 participating institutions and personal collections in 2023.
Automated insulin delivery systems are automated (or semi-automated) systems designed to assist people with insulin-requiring diabetes, by automatically adjusting insulin delivery in response to blood glucose levels. Currently available systems (as of October 2020) can only deliver (and regulate delivery of) a single hormone—insulin. Other systems currently in development aim to improve on current systems by adding one or more additional hormones that can be delivered as needed, providing something closer to the endocrine functionality of the pancreas. The endocrine functionality of the pancreas is provided by islet cells which produce the hormones insulin and glucagon. Artificial pancreatic technology mimics the secretion of these hormones into the bloodstream in response to the body's changing blood glucose levels. Maintaining balanced blood sugar levels is crucial to the function of the brain, liver, and kidneys. Therefore, for people with diabetes, it is necessary that the levels be kept balanced when the body cannot produce insulin itself. Automated insulin delivery (AID) systems are often referred to using the term artificial pancreas, but the term has no precise, universally accepted definition. For uses other than automated insulin delivery, see Artificial pancreas (disambiguation).
Sources: en.wikipedia.org
== General == Vegetarian bacon – sometimes made from tempeh. Vegetarian sausage Vegetarian hot dog Carrot hot dog Vegetarian burger Vegan chicken nuggets – made from pea protein, soy protein, textured vegetable protein, and wheat gluten Tofurkey – faux turkey, a meat substitute in the form of a loaf or casserole of vegetarian protein, usually made from tofu (soybean protein) or seitan (wheat protein) with a stuffing made from grains or bread, flavored with a broth and seasoned with herbs and spices Cauliflower – coated in flour and baked or fried to imitate chicken wings or steak Leaf protein concentrate Meat extender – sometimes but not always soy-based Mock duck Nut roast Seitan – a food made from wheat gluten, with wheat being a grain.
Local-only alerts use a siren or flashing beacon—such as the battery-powered “Freeze Flash” window light—to attract the attention of neighbours. Remote-notification alarms contact designated recipients through telephone, SMS, e-mail, or push notification, a critical feature for unattended properties.
== Mutations == Mutations or deletions in the AZF genes are associated with inability or lessened ability to create sperm. It may cause azoospermia (not having any measurable level of sperm in semen). Deletions in the USP9Y gene, which is located within AZF1, are usually associated with inability to form sperm.
=== Food fortification === The United States Food and Drug Administration lists retinyl acetate as "Generally Recognized as Safe" (GRAS) for use as a nutrient supplement in foods (21 CFR 184.1930). It is commonly added to margarine, plant‑based milk, breakfast cereals and staple oils in low‑ and middle‑income countries to prevent vitamin A deficiency.
=== General characteristics of the active substance === Salmon calcitonin is rapidly absorbed and eliminated. Peak plasma concentrations are attained within the first hour of administration. Animal studies have shown that calcitonin is primarily metabolised via proteolysis in the kidney following parenteral administration. The metabolites lack the specific biological activity of calcitonin. Bioavailability following subcutaneous and intramuscular injection in humans is high and similar for the two routes of administration (71% and 66%, respectively). Calcitonin has short absorption and elimination half-lives of 10–15 minutes and 50–80 minutes, respectively. Salmon calcitonin is primarily and almost exclusively degraded in the kidneys, forming pharmacologically inactive fragments of the molecule. Therefore, the metabolic clearance is much lower in patients with end-stage kidney failure than in healthy subjects. However, the clinical relevance of this finding is not known. Plasma protein binding is 30% to 40%.
Sources: en.wikipedia.org
The basic mammalian body type is quadrupedal, with most mammals using four limbs for terrestrial locomotion; but in some, the limbs are adapted for life at sea, in the air, in trees or underground. The bipeds have adapted to move using only the two lower limbs, while the rear limbs of cetaceans and the sea cows are mere internal vestiges. Mammals range in size from the 30–40 millimetres (1.2–1.6 in) bumblebee bat to the 30 metres (98 ft) blue whale—possibly the largest animal to have ever lived. Maximum lifespan varies from two years for the shrew to 211 years for the bowhead whale. All modern mammals give birth to live young, except the five species of monotremes, which lay eggs. The most species-rich group is the viviparous placental mammals, so named for the temporary organ (placenta) used by offspring to draw nutrition from the mother during gestation. Most mammals are intelligent, with some possessing large brains, self-awareness, and tool use. Mammals can communicate and vocalize in several ways, including the production of ultrasound, scent marking, alarm signals, singing, echolocation; and, in the case of humans, complex language. Mammals can organize themselves into fission–fusion societies, harems, and hierarchies—but can also be solitary and territorial. Most mammals are polygynous, but some can be monogamous or polyandrous. Domestication of many types of mammals by humans played a major role in the Neolithic Revolution, and resulted in farming replacing hunting and gathering as the primary source of food for humans.
=== Broadcasting === While attending college in Drury, Barker worked his first media job at KTTS-FM Radio in Springfield. He and his wife left Springfield and moved to Lake Worth Beach, Florida, and Barker was news editor and announcer at nearby WWPG 1340 AM in Palm Beach (now WPBR in Lantana). In 1950, he moved to California to advance his broadcasting career. Barker was given his own radio show, The Bob Barker Show, which ran for the next six years from Burbank. He was hosting an audience-participation radio show on KHJ (AM) in Los Angeles when game show producer Ralph Edwards, who was looking for a new host to replace Jack Bailey on the daytime-television version of his long-running show, Truth or Consequences, happened to be listening and liked Barker's voice and style.
The 2013 documentary Pandora's Promise presents the integral fast reactor as an alternative to fossil-fuel power, with commentary from former Argonne managers Len Koch and Chuck Till. Recycling nevertheless leaves radioactive wastes requiring disposal, including long-lived fission products and wastes from fuel processing. According to the movie, one pound of uranium provides as much energy as 5,000 barrels of oil.
== Production and synthesis == γ-Butyrolactone is produced industrially by dehydrogenation of 1,4-butanediol at a temperature of 180–300 °C and atmospheric pressure in the presence of a copper catalyst.
On February 19, 2026, Hims & Hers announced an agreement to acquire the Australian digital health company Eucalyptus Health, operator of the Juniper, Pilot, and Kin telehealth brands, for consideration of up to $1.15 billion. Following the completion of the Eucalyptus acquisition, Hims launched in Australia on 1st September 2026, initially offering men's health treatments and weight-loss medication, including branded GLP-1 products. Alongside the launch, the company began retiring Eucalyptus's Pilot men's-health brand and rebranding under the Hims name. The company announced that it would transition existing Pilot clinicians to its platform and plans to introduce women's health services in Australia later in 2026 through their existing Juniper brand.
Sources: en.wikipedia.org
A responder analysis counts participants who cross a threshold, such as five or ten percent weight loss. It complements average percent change by showing how widely results are distributed. The two measures can diverge when a subset of participants loses a large amount.
Mechanistic measures such as energy expenditure and liver fat change come from small substudies and should be read as preliminary. Long-term clinical outcomes are not yet available. Average weight loss figures are better supported than explanations for how the loss is achieved.
Endpoints reported at different weeks, in different baseline BMI ranges, or under different dose-escalation schedules are not directly comparable. Studies in type 2 diabetes often show smaller weight changes than studies in obesity without diabetes. Reporting the population alongside the number keeps comparisons honest.
It is a synthetic peptide classified as a triple receptor agonist. It engages the GLP-1, GIP, and glucagon receptors at once. It is investigated for metabolic and weight-related conditions rather than approved for general use.